How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

101,779 results for

Pharmaceutical Representative

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy

MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy Interventional procedures guidance Published: 4 March 2020 www.nice.org.uk/guidance/ipg671 Your responsibility Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account (...) Evidence on the safety of MRI-guided laser interstitial thermal therapy for drug- resistant epilepsy shows there are serious but well-recognised safety concerns. Evidence on its efficacy is limited in quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. 1.2 Clinicians wishing to do MRI-guided laser interstitial thermal therapy for drug- resistant epilepsy should: • Inform the clinical governance leads in their NHS

2020 National Institute for Health and Clinical Excellence - Interventional Procedures

2. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

, Los Angeles Los Angeles, CA Nancy Lane, M.D. Director and Distinguished Professor Center for Musculoskeletal Health and Department of Internal Medicine University of California at Davis, School of Medicine Sacramento, California Jasvinder Singh, M.D., M.P.H. Division of Rheumatology University of Alabama Birmingham, AL vii Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Structured Abstract Objective. To summarize the effects of long-term (...) Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Comparative Effectiveness Review Number 218 RComparative Effectiveness Review Number 218 Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600

2019 Effective Health Care Program (AHRQ)

3. Felbamate add-on therapy for drug-resistant focal epilepsy. (Abstract)

Felbamate add-on therapy for drug-resistant focal epilepsy. This is an updated version of the Cochrane Review previously published in 2017.Epilepsy is a chronic and disabling neurological disorder, affecting approximately 1% of the population. Up to 30% of people with epilepsy have seizures that are resistant to currently available antiepileptic drugs and require treatment with multiple antiepileptic drugs in combination. Felbamate is a second-generation antiepileptic drug that can be used (...) as add-on therapy to standard antiepileptic drugs.To evaluate the efficacy and tolerability of felbamate versus placebo when used as an add-on treatment for people with drug-resistant focal-onset epilepsy.For the latest update we searched the Cochrane Register of Studies (CRS Web), MEDLINE, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP), on 18 December 2018. There were no language or time restrictions. We reviewed the reference lists of retrieved studies

2019 Cochrane

4. 3-year treatment outcomes of water vapor thermal therapy (Rezūm System) compared to doxazosin, finasteride and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. (Abstract)

3-year treatment outcomes of water vapor thermal therapy (Rezūm System) compared to doxazosin, finasteride and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. We evaluated the long-term outcomes of treatment of lower urinary tract symptoms due to benign prostatic hyperplasia to compare a 1-time water vapor thermal therapy procedure with daily medical therapy in cohorts from the MTOPS (Medical Therapy (...) of Prostatic Symptoms) study.Results in the treatment arm of a randomized, controlled trial of thermal therapy using the Rezūm® System were compared to MTOPS subjects treated with doxazosin and/or finasteride. Evaluations were restricted to medical therapy subjects, representing 1,140 of the original 3,047 (37.4%), with a prostate volume of 30 to 80 cc and an International Prostate Symptom Score of 13 or greater to include men who met key criteria of the Rezūm and MTOPS trials. Outcomes were compared

2018 Journal of Urology Controlled trial quality: uncertain

5. Drug therapy for symptoms associated with anxiety in adult palliative care patients. Full Text available with Trip Pro

Drug therapy for symptoms associated with anxiety in adult palliative care patients. This is an update of a Cochrane Review first published in 2004 (Issue 1) and previously updated in 2012 (Issue 10). Anxiety is common in palliative care patients. It can be a natural response to the complex uncertainty of having a life-limiting illness or impending death, but it may represent a clinically significant issue in its own right.To assess the effectiveness of drug therapy for treating symptoms (...) of drug therapy for the treatment of symptoms of anxiety in adult palliative care patients, that is, people with a known progressive life-limiting illness that is no longer responsive to curative treatment, including advanced heart, respiratory and neurological diseases (including dementia). Comparator treatments included placebo; another drug therapy or different dose schedule; or a non-drug intervention such as counselling, cognitive behaviour therapies or relaxation therapies.Two review authors

2017 Cochrane

6. Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients

Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients LABORATORY MEDICINE PRACTICE GUIDELINES EDITED BY LORALIE J. LANGMAN AND PAUL J. JANNETTO Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients Co-Sponsored byLABORATORY MEDICINE PRACTICE GUIDELINES Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients Loralie J. Langman Committee Chair Department of Laboratory Medicine and Pathology Mayo Clinic (...) References 101 Table of ContentsLABORATORY MEDICINE PRACTICE GUIDELINES Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients 5 Executive Summary Introduction The American Association for Clinical Chemistry (AACC) Acad- emy, formerly the National Academy of Clinical Biochemistry (NACB), has developed a laboratory medicine practice guidelines (LMPG) for using laboratory tests to monitor drug therapy in pain management patients. The scope and purpose of this guideline

2018 American Academy of Pain Medicine

7. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update July 2018 In partnership withComparative Effectiveness Review Number 211 Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov and Patient (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Donahue KE, Gartlehner G, Schulman ER, Jonas B, Coker-Schwimmer E, Patel SV, Weber RP, Lohr KN, Bann C, Viswanathan M. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update. Comparative Effectiveness Review No. 211. (Prepared by the RTI International–University of North Carolina

2018 Effective Health Care Program (AHRQ)

8. Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

Diabetes Canada, have acknowledged that there may be a role for adjunctive therapy in some T1D patients. 10,23,40 In the US, pramlintide acetate injection (Symlin) is the only noninsulin drug approved for adjunctive treatment of T1D. 13,29 Metformin, a T2D medication, is mentioned by Diabetes Canada and the American Diabetes Association for off-label use to reduce insulin requirements and total cholesterol/low-density lipoprotein ratios, 10,17,23 with the caveat that it does not improve hemoglobin A1C (...) Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? | CADTH.ca CADTH Document Viewer Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Table of Contents Search this document Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? January 2018 Summary There are two major

2018 CADTH - Issues in Emerging Health Technologies

9. The effect of SENATOR (Software ENgine for the Assessment and optimisation of drug and non-drug Therapy in Older peRsons) on incident adverse drug reactions (ADRs) in an older hospital cohort - Trial Protocol. Full Text available with Trip Pro

The effect of SENATOR (Software ENgine for the Assessment and optimisation of drug and non-drug Therapy in Older peRsons) on incident adverse drug reactions (ADRs) in an older hospital cohort - Trial Protocol. The aim of this trial is to evaluate the effect of SENATOR software on incident, adverse drug reactions (ADRs) in older, multimorbid, hospitalized patients. The SENATOR software produces a report designed to optimize older patients' current prescriptions by applying the published STOPP (...) and START criteria, highlighting drug-drug and drug-disease interactions and providing non-pharmacological recommendations aimed at reducing the risk of incident delirium.We will conduct a multinational, pragmatic, parallel arm Prospective Randomized Open-label, Blinded Endpoint (PROBE) controlled trial. Patients with acute illnesses are screened for recruitment within 48 h of arrival to hospital and enrolled if they meet the relevant entry criteria. Participants' medical history, current prescriptions

2019 BMC Geriatrics Controlled trial quality: predicted high

10. New Drugs for Type 2 Diabetes: Second-Line Therapy — Recommendations Report

therapies for second- and third-line treatment of type 2 diabetes. Since 2013, several new drugs and a new medication class (sodium-glucose cotransporter-2 [SGLT-2] inhibitors) have been released on the market in Canada. During the same period, CADTH Common Drug Review has provided multiple recommendations in technology assessments of individual drugs for type 2 diabetes. Given the evolving landscape of the treatment of type 2 diabetes, an update of the previous review has been undertaken. This document (...) on varying background therapies and pragmatically allowed for continuation of whatever the existing background therapy was at baseline. Background therapies were no treatment (i.e., they were drug-naive and starting the study intervention); monotherapy (they were taking a single antidiabetic medication or insulin and added the study intervention to that therapy); dual therapy; and combinations of more than two therapies. There were limited data regarding proportions of background therapy for the enrolled

2017 CADTH - Plasma Products

11. New Drugs for Type 2 Diabetes: Second-Line Therapy — Recommendations Report

therapies for second- and third-line treatment of type 2 diabetes. Since 2013, several new drugs and a new medication class (sodium-glucose cotransporter-2 [SGLT-2] inhibitors) have been released on the market in Canada. During the same period, CADTH Common Drug Review has provided multiple recommendations in technology assessments of individual drugs for type 2 diabetes. Given the evolving landscape of the treatment of type 2 diabetes, an update of the previous review has been undertaken. This document (...) on varying background therapies and pragmatically allowed for continuation of whatever the existing background therapy was at baseline. Background therapies were no treatment (i.e., they were drug-naive and starting the study intervention); monotherapy (they were taking a single antidiabetic medication or insulin and added the study intervention to that therapy); dual therapy; and combinations of more than two therapies. There were limited data regarding proportions of background therapy for the enrolled

2017 CADTH - Plasma Products

12. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders Full Text available with Trip Pro

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease with a broad clinical spectrum and variable course. It can involve musculoskeletal structures as well as skin, nails, eyes, and gut. The management of PsA has changed tremendously in the last decade, thanks to an earlier diagnosis, an advancement in pharmacological therapies (...) , and a wider application of a multidisciplinary approach. The commercialization of tumor necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab) as well as interleukin (IL)-12/23 (ustekinumab) and IL-17 (secukinumab) inhibitors is representative of a revolution in the treatment of PsA. No evidence-based strategies are currently available for guiding the rheumatologist to prescribe biological drugs. Several international and national recommendation sets

2017 Open access rheumatology : research and reviews

13. Viral load suppression and acquired HIV drug resistance in adults receiving antiretroviral therapy in Viet Nam: results from a nationally representative survey Full Text available with Trip Pro

Viral load suppression and acquired HIV drug resistance in adults receiving antiretroviral therapy in Viet Nam: results from a nationally representative survey The purpose of this survey was to estimate the prevalence of viral load (VL) suppression and emergence of HIV drug resistance (HIVDR) among individuals receiving antiretroviral therapy (ART) for 36 months or longer in Viet Nam using a nationally representative sampling method.The survey was conducted between May and August 2014 using (...) interval [CI]: 69.0-81.9 months), and 93.7% of the patients were receiving non-nucleoside reverse transcriptase inhibitor-based regimens. Of the 365 individuals, 345 (94.7%, 95% CI: 64.1-99.4%) had VL below 1000 copies/mL and 19 (4.6%, 95% CI: 2.8--7.5) had HIVDR mutations.Our nationally representative survey found a high level of VL suppression and a low prevalence of HIVDR among individuals who received ART for at least 36 months in Viet Nam. Continued surveillance for HIVDR is important

2018 Western Pacific surveillance and response journal : WPSAR

14. Functional Family Therapy (FFT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Full Text available with Trip Pro

Functional Family Therapy (FFT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Functional Family Therapy (FFT) for Young People in Treatment for Non‐opioid Drug Use: A Systematic Review - Filges - 2015 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Functional Family Therapy (FFT) for Young People (...) version of this article with your friends and colleagues. Copy URL Share a link Share on 1 The terms ‘use’, ‘abuse’ and ‘dependence’ are often used interchangeably and refer to an addiction stage of non‐medical drug usage. of the kind that persists beyond the experimentation phase is a severe problem worldwide ( ). Abuse of non‐opioid drugs such as cannabis, amphetamine and cocaine is strongly associated with a broad range of negative health implications such as traffic accidents, sexually transmitted

2015 Campbell Collaboration

15. Family Behavior Therapy (FBT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Full Text available with Trip Pro

Family Behavior Therapy (FBT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Family Behavior Therapy (FBT) for Young People in Treatment for Non‐opioid Drug Use: A Systematic Review - Lindstrøm - 2015 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Family Behavior Therapy (FBT) for Young People in Treatment (...) ‐medical drug usage. that persists beyond curious experimentation is a severe problem worldwide (United Nations Office of Drugs and Crime . Use of non‐opioid drugs such as cannabis, amphetamine and cocaine is strongly associated with a range of health and social problems, including delinquency, poor scholastic attainment, fatal automobile accidents, suicide and other individual and public calamities ( ; ; ; Office of National Drug Control Policy ; ). More than 20 million of the 12 to 25 year‐olds

2015 Campbell Collaboration

16. Cognitive?Behavioural Therapies for Young People in Outpatient Treatment for Non?Opioid Drug Use: A Systematic Review Full Text available with Trip Pro

Cognitive?Behavioural Therapies for Young People in Outpatient Treatment for Non?Opioid Drug Use: A Systematic Review Cognitive‐Behavioural Therapies for Young People in Outpatient Treatment for Non‐Opioid Drug Use: A Systematic Review - Filges - 2015 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Cognitive‐Behavioural Therapies (...) below to share a full-text version of this article with your friends and colleagues. Copy URL Share a link Share on 1 The terms use, abuse and dependence are used interchangeably throughout the review and refer to an addiction stage of non‐medical usage. that persists beyond curious experimentation is a severe problem worldwide ( ). Drugs such as cannabis, amphetamines, ecstasy and cocaine, referred to in this review as non‐opioids 2 Use of ketamine, nitrous oxide and inhalants, e.g. glue and petrol

2015 Campbell Collaboration

17. Multidimensional Family Therapy (MDFT) for Young People in Treatment for Non?opioid Drug Abuse: A Systematic Review Full Text available with Trip Pro

and solving. Second, guided by this multidimensional assessment, the model addresses common root factors underlying a range of emotional and behavioral symptoms that co‐occur with young persons' drug abuse. MDFT is organized into phases, based upon knowledge of what is considered to be normal cognitive and emotional development for young people. Each phase represents one of several targets for assessment, intervention, and change, and the therapist will not progress to the next phase until the therapy has (...) Multidimensional Family Therapy (MDFT) for Young People in Treatment for Non?opioid Drug Abuse: A Systematic Review Multidimensional Family Therapy (MDFT) for Young People in Treatment for Non‐opioid Drug Abuse: A Systematic Review - Filges - 2015 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Multidimensional Family Therapy (MDFT

2015 Campbell Collaboration

18. Ending pharmaceutical sales representatives' access to hospitals and students

Spotlight In the November issue of Prescrire International: Ending pharmaceutical sales representatives' access to hospitals and students FREE DOWNLOAD In-person promotion of drugs to healthcare professionals by pharmaceutical sales representatives, known as pharmaceutical detailing, has been shown to influence doctors' prescribing behaviour. A US study looked at ways to limit this influence. Full text available for free download. Summary A large-scale case-control study has evaluated policies (...) (October 2018) Knowing how to say "No thank you" is crucial (April 2017) Guard against drug companies' influence on healthcare professionals, starting with medical students (June 2013) Student associations drive pharmaceutical companies off campus (July 2016) | | | Prescrire Your change of address has been received and will be processed promptly but will not appear instantaneously Prescrire Your message has been sent

2018 Prescrire

19. Becoming a ‘pharmaceutical person’: Medication use trajectories from age 26 to 38 in a representative birth cohort from Dunedin, New Zealand Full Text available with Trip Pro

Becoming a ‘pharmaceutical person’: Medication use trajectories from age 26 to 38 in a representative birth cohort from Dunedin, New Zealand Despite the abundance of medications available for human consumption, and frequent concerns about increasing medicalization or pharmaceuticalization of everyday life, there is little research investigating medicines-use in young and middle-aged populations and discussing the implications of young people using increasing numbers of medicines (...) and becoming pharmaceutical users over time. We use data from a New Zealand longitudinal study to examine changes in self-reported medication use by a complete birth cohort of young adults. Details of medications taken during the previous two weeks at age 38 are compared to similar data collected at ages 32 and 26, and by gender. Major drug categories are examined. General use profiles and medicine-types are considered in light of our interest in understanding the formation of the young and middle-aging

2017 SSM - population health

20. Noncoding RNAs in cancer therapy resistance and targeted drug development. Full Text available with Trip Pro

Noncoding RNAs in cancer therapy resistance and targeted drug development. Noncoding RNAs (ncRNAs) represent a large segment of the human transcriptome and have been shown to play important roles in cellular physiology and disease pathogenesis. Increasing evidence on the functional roles of ncRNAs in cancer progression emphasizes the potential of ncRNAs for cancer treatment. Here, we summarize the roles of ncRNAs in disease relapse and resistance to current standard chemotherapy (...) application. The next approved nucleic acid drug to treat cancer patients may realistically be on the horizon.

2019 Journal of hematology & oncology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>